Main Menu

TG Therapeutics, Inc.


Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of TG Therapeutics, Inc. ("TG" or the "Company") on behalf of stockholders.  A class action complaint has been filed against TG.  The complaint alleges that defendants made a series of misrepresentations concerning the safety and commercial prospects of the Company's two most important drugs, Ublituximab and Umbralisib.  Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain FDA approval of the Umbralisib MZL/FL New Drug Application ("NDA"), the U2 Biologics License Application ("BLA"), the U2 supplemental NDA, or the Ublituximab RMS BLA in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib’s clinical and/or commercial prospects; and (iv) therefore, the Company’s public statements were materially false and misleading at all relevant times.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 06/15/2024

* Indicates a required field.

Back to Page